Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 2/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 13/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 11/20 | 0.38 |
| ▸ | ADK | P55263 | 1/20 | 0.36 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.35 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.35 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19379653 | 0.84 | FAP (0.37) | FAPPRMT5WDR77ADKSTING1 | |
| SCHEMBL19401320 | 0.83 | PRMT5 (0.41) | FAPPRMT5WDR77 | |
| SCHEMBL21413061 | 0.77 | FAP (0.37) | FAPPRMT5WDR77ADKSTING1 | |
| SCHEMBL19397140 | 0.76 | PRMT5 (0.36) | PRMT5WDR77ADK | |
| SCHEMBL19397138 | 0.75 | PRMT5 (0.36) | PRMT5WDR77ADK | |
| SCHEMBL19397136 | 0.73 | PRMT5 (0.36) | PRMT5WDR77ADK | |
| SCHEMBL31228378 | 0.73 | CYP3A4 (0.47) | PRMT5WDR77 | |
| SCHEMBL31228091 | 0.73 | CYP3A4 (0.47) | PRMT5WDR77 | |
| SCHEMBL31228132 | 0.73 | CYP3A4 (0.47) | PRMT5WDR77 | |
| SCHEMBL31228195 | 0.72 | PRMT5 (0.48) | PRMT5WDR77ADKDNMT1DNMT3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988416-B2 | Alkynyl nucleoside analogs as inhibitors of human rhinovirus | NOVARTIS AG (CH) | 2018-06-05 | — | — | US | disclosed |
| US-20170275329-A1 | ALKYNYL NUCLEOSIDE ANALOGS AS INHIBITORS OF HUMAN RHINOVIRUS | NOVARTIS INSTITUTE FOR TROPICAL DISEASES PTE LTD (SG) | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275329-A1 | ALKYNYL NUCLEOSIDE ANALOGS AS INHIBITORS OF HUMAN RHINOVIRUS | RNASEH1, ENTPD5, SARNP | FAP 276/4885PRMT5 1834/4885WDR77 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.